The International Association for Biologicals (IABs) in cooperation with the Royal Society of Medicine (UK) and the John Wayne Cancer Institute is proud to present our first Therapeutic Cancer Vaccines conference. The Program Committee, which includes Dr. Raj Puri (FDA) and Dr. Howard Streicher (NCI), has structured the program to build upon the FDA/NCI workshop that was held in December 1998. This conference will bring together industry, regulatory and academic professionals to share up-to-date clinical and regulatory information on cancer vaccine development.

We will review both progress and emerging issues in cancer vaccine development that have occurred since 1998. The conference places an emphasis on cancer vaccines in late stage development, but it also will include presentations and discussions on exciting earlier stage products. The overall objective of the conference is to identify and address issues in cancer vaccine development in order to move forward efficiently to product approvals.

This is an excellent opportunity to learn about progress in the clinical trials of several late stage development programs as well as to hear updates on regulatory positions in the USA, Canada, Europe, and Australia. Valuable discussions will be presented on:

· Discovery of novel tumor antigens
· Regulatory considerations in therapeutic cancer vaccine development
· Allogeneic and autologous cancer cell vaccines
· Acellular cancer cell vaccines
· Recombinant and peptide cancer vaccines
· Dendritic cell cancer vaccines
· Immune responses to cancer vaccines